This editorial refers to ‘Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up’† by E.S. Brilakis et al. , on page 137 Over the past 50 years, the age-adjusted mortality rate from cardiovascular disease has decreased substantially. Despite the improved mortality rate, there is evidence that actual cardiovascular event rates remain relatively unchanged (i.e. more people are surviving acute events), and heart disease and stroke continue to be leading causes of death in Western societies.1 Intensive research efforts are currently under way with the goal of further reducing the global burden of cardiovascular disease. An improved understanding of vascular biology and the pathogenesis of atherosclerosis—including the role of inflammatory processes—may prove helpful in achieving this goal. Atherosclerosis is a condition involving numerous complex processes within the vessel wall that can be characterized as an inflammatory response to injury. The ‘injury’ is most likely attributable to oxidized low-density lipoprotein (LDL) cholesterol, and the inflammatory response is mediated predominantly by monocyte-derived macrophages and T-lymphocytes.2 Together, these cells, along with endothelial cells and vascular smooth muscle cells, express or enhance the expression of inflammatory mediators—cytokines, chemokines, adhesion molecules, growth factors, and other bioactive substances—that play an important role in each stage of atherosclerosis, from initial plaque formation to plaque (in)stability/rupture. Improvements in the understanding of vascular biology have led investigators to evaluate whether certain components of the inflammatory processes may be helpful in identifying high-risk individuals with … *Corresponding author. Tel.: +1 610 270-7227; fax: +1 610 270-6206 E-mail address : colin.h.macphee{at}gsk.com
Read full abstract